Allergy Diagnostics Market

The global Allergy Diagnostics market is projected to reach USD 9.8 billion by 2029 from USD 5.3 billion in 2024, at a CAGR of 11.0% during the forecast period. One of the main factors propelling this market's expansion is the rising incidence of allergy illnesses. The primary drivers of this market's expansion are the availability of health insurance and the increasing amount of money that companies are investing in Allergy Diagnostics.

The Allergy Diagnostics market is consolidated and is dominated by few players. The major players operating in this market are Thermo Fisher Scientific Inc., (US), Siemens Healthineers AG (Germany), Danaher (US), and Canon, Inc. (Japan) [Minaris Medical America, Inc. (US)].

To know about the assumptions considered for the study download the pdf brochure

Danaher Corporation (US)

Danaher held the largest share of the Allergy Diagnostics market in 2023. Within the Core Lab Diagnostics business subsegment, Danaher operates in the Allergy Diagnostics market through its subsidiary Beckman Coulter. The Core Lab business provides biomedical testing equipment, systems, and associated consumables to end customers so they can assess and examine bodily fluids, cells, and other materials. The data produced is utilized in hospital, outpatient, and doctor's office settings to diagnose illnesses, track and direct therapy and treatment, help manage chronic conditions, and evaluate patient status. Products from Beckman Coulter include tools and consumables used in allergy testing.

Thermo Fishers Scientific Inc. (US)

Thermo Fisher Scientific Inc., a US-based company, is the second largest player in the Allergy Diagnostics market, in 2023. The company's wide range of products is principally responsible for its dominant market position. The company's Phadia equipment are widely used for allergy testing in laboratories and other healthcare settings. Additionally, the company's robust customer base is mostly due to its wide regional presence. More than 400,000 clients are served by the corporation in the pharmaceutical and biotech industries, hospitals, clinical diagnostic labs, government agencies, universities, and research facilities, in addition to environments, industrial quality, and process control settings.

Minaris Medica America, Inc. (Canon, Inc. [Japan])

Minaris Medical, formerly known as Hitachi Chemical Co. Ltd., held the third position in the Allergy Diagnostics market in 2023. This company is one of the international providers of in vitro multiplex Allergy Diagnostics. A thorough panel test for environmental and dietary allergens is the OPTIGEN Allergen-Specific IgE Assay. To provide the medical community with the newest in vitro allergy testing technology, Minaris collaborates with labs, industry experts, and distributors globally. Currently, Minaris' allergy testing products are offered in more than 20 countries worldwide.

Related Reports:

Allergy Diagnostics Market by Product & Service (Consumables, Instruments (Immunoassay Analyzer, Luminometer), Services), Test Type (In Vivo (Skin Prick, Patch), In Vitro), Allergen (Food, Inhaled, Drug), End User, & Region - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]